A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma
Patel, M. R. Ahearne, M. Fox, C. Lewis, D. J. Higgins, M. Schwartz, B. E. Beer, P. A. Tees, M. T.
Patel, M. R.
Ahearne, M.
Fox, C.
Lewis, D. J.
Higgins, M.
Schwartz, B. E.
Beer, P. A.
Tees, M. T.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Patel MR, Ahearne M, Linton K, Fox C, Lewis DJ, Higgins M, et al. A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005456.